|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
70,650,000 |
Market
Cap: |
4.01(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.62 - $89.12 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
61,438 |
159,721 |
184,721 |
409,721 |
Total Sell Value |
$4,291,798 |
$10,834,513 |
$12,456,407 |
$25,314,056 |
Total People Sold |
3 |
3 |
3 |
3 |
Total Sell Transactions |
7 |
12 |
13 |
22 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Woiwode Thomas |
Director |
|
2018-04-20 |
4 |
AS |
$0.00 |
$0 |
I/I |
(592,918) |
0 |
|
- |
|
Woiwode Thomas |
Director |
|
2018-04-20 |
4 |
A |
$0.00 |
$0 |
I/I |
92,918 |
92,918 |
|
- |
|
Dylan-Hyde Tyler |
Chief Legal Officer |
|
2018-01-16 |
4 |
AS |
$28.00 |
$1,850,255 |
D/D |
(66,000) |
25,204 |
|
- |
|
Dylan-Hyde Tyler |
Chief Legal Officer |
|
2018-01-16 |
4 |
OE |
$12.57 |
$263,970 |
D/D |
21,000 |
45,094 |
|
- |
|
Bayer Global Investments B.v. |
10% Owner |
|
2018-01-05 |
4 |
B |
$22.75 |
$11,999,988 |
I/I |
527,472 |
5,632,802 |
1.5 |
- |
|
Emster Kurt Von |
Director |
|
2018-01-05 |
4 |
B |
$22.75 |
$1,499,999 |
I/I |
65,934 |
1,887,202 |
2.1 |
- |
|
Emster Kurt Von |
Director |
|
2018-01-05 |
4 |
AS |
$26.96 |
$2,489,406 |
I/I |
(92,337) |
1,821,268 |
|
- |
|
Dylan-Hyde Tyler |
Chief Legal Officer |
|
2018-01-02 |
4 |
AS |
$20.55 |
$822,500 |
D/D |
(38,000) |
70,204 |
|
- |
|
Dylan-Hyde Tyler |
Chief Legal Officer |
|
2018-01-02 |
4 |
OE |
$12.57 |
$100,560 |
D/D |
8,000 |
78,204 |
|
- |
|
Emster Kurt Von |
Director |
|
2018-01-02 |
4 |
AS |
$26.76 |
$1,010,123 |
I/I |
(37,754) |
1,913,605 |
|
- |
|
Dylan-Hyde Tyler |
Chief Legal Officer |
|
2017-12-29 |
4 |
AS |
$21.75 |
$689,055 |
D/D |
(30,300) |
100,204 |
|
- |
|
Dylan-Hyde Tyler |
Chief Legal Officer |
|
2017-12-29 |
4 |
OE |
$12.57 |
$203,909 |
D/D |
15,300 |
124,274 |
|
- |
|
Dylan-Hyde Tyler |
Chief Legal Officer |
|
2017-12-28 |
4 |
AS |
$21.75 |
$15,225 |
D/D |
(700) |
115,204 |
|
- |
|
Dylan-Hyde Tyler |
Chief Legal Officer |
|
2017-12-28 |
4 |
OE |
$14.43 |
$10,101 |
D/D |
700 |
115,904 |
|
- |
|
Dylan-Hyde Tyler |
Chief Legal Officer |
|
2017-12-22 |
4 |
AS |
$20.55 |
$308,250 |
D/D |
(15,000) |
115,204 |
|
- |
|
Woiwode Thomas |
Director |
|
2017-12-22 |
4 |
AS |
$20.29 |
$62,070 |
D/D |
(3,059) |
4,959 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2017-12-22 |
4 |
AS |
$20.30 |
$528,237 |
D/D |
(26,016) |
27,724 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2017-12-21 |
4 |
OE |
$1.81 |
$27,150 |
D/D |
15,000 |
148,560 |
|
- |
|
Dylan-Hyde Tyler |
Chief Legal Officer |
|
2017-12-15 |
4 |
AS |
$18.90 |
$283,496 |
D/D |
(15,000) |
130,204 |
|
- |
|
Celgene Corp /de/ |
10% Owner |
|
2017-12-04 |
4 |
S |
$19.47 |
$593,543 |
I/I |
(30,485) |
3,722,534 |
|
- |
|
Celgene Corp /de/ |
10% Owner |
|
2017-12-01 |
4 |
S |
$19.10 |
$1,680,628 |
I/I |
(87,991) |
3,753,019 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2017-12-01 |
4 |
A |
$19.12 |
$509,873 |
D/D |
26,667 |
133,560 |
|
- |
|
Celgene Corp /de/ |
10% Owner |
|
2017-11-30 |
4 |
S |
$19.04 |
$241,161 |
I/I |
(12,666) |
3,841,010 |
|
- |
|
Celgene Corp /de/ |
10% Owner |
|
2017-11-29 |
4 |
S |
$19.25 |
$82,063 |
I/I |
(4,263) |
3,853,676 |
|
- |
|
Celgene Corp /de/ |
10% Owner |
|
2017-11-28 |
4 |
S |
$19.22 |
$97,638 |
I/I |
(5,080) |
3,857,939 |
|
- |
|
483 Records found
|
|
Page 13 of 20 |
|
|